Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
NVAXthis companyNovavax, Inc.	$11.11	2.47×	-8.52×	0.97×	2.23×	-709.5%	93.7%	50.1%	39.2%	-344.7%	78.0%	-23.0%	-1.95×	0.02×	24.98×	2.13×	0.0%	0	-5.59	2	B-
ARCTArcturus Therapeutics Holdings Inc.	$9.87	-2.55×	0.78×	2.5×	0.61×	-135.5%	95.5%	-111.5%	-97.9%	-30.7%	-31.4%	-44.2%	0.12×	3.28×	0×	6.64×	0.0%	1	-0.16	2	C
EBSEmergent BioSolutions Inc.	$6.17	12.61×	1.27×	0.89×	4.32×	-42.8%	47.2%	14.8%	7.1%	10.1%	5.9%	23.7%	1.09×	1.54×	1.86×	5.01×	0.0%	4	0.26	1	C-
GOVXGeoVax Labs, Inc.	$0.16	-0.19×	1.07×	1.65×	-0.09×	12.2%	-628.0%	-869.3%	-862.3%	-561.2%	-463.5%	-524.2%	0.22×	0.1×	0×	2.74×	0.0%	2	-62.32	2	C+
INOInovio Pharmaceuticals, Inc.	$1.49	-0.96×	3.39×	1,248.52×	-0.57×	-54.3%	100.0%	-132871.3%	-130000.0%	-352.5%	-259.4%	-109.0%	0.39×	0.43×	0×	1.4×	0.0%	0	-55.57	1	C-
MRNAModerna, Inc.	$273.68	-4.06×	1.33×	5.9×	-4.23×	-100.6%	55.3%	-158.1%	-145.2%	-32.6%	-29.7%	-18.0%	0.22×	0.27×	-307.4×	3.29×	0.0%	3	9.73	1	D+
Peer median	—	-0.96×	1.27×	2.5×	-0.09×	-54.3%	55.3%	-158.1%	-145.2%	-32.6%	-31.4%	-44.2%	0.22×	0.43×	0×	3.29×	0.0%	2	-0.16	1	—